I know I’m preaching to the choir here to some extent, but just stop and think: how could you or anyone KNOW what was contained in ANY of Gates’ fetishistic concoctions? Do you have the ability to run a chemical assay? Of course not. You are being asked to trust some of the most heinous criminals to ever live – lying liars who lie, and have as their open, explicit goal the reduction of the human population by something like 85%.
Bill and Melinda Gates already clandestinely injected sterilants into millions of Kenyans under the guise of tetanus shots. When caught, they lyingly claimed that there was a “contamination” at the production facility. Yeah. Riiiight.
Here is a firm that is totally in bed with the Bill and Melinda Gates Foundation producing microneedle patch slow-release drug systems. Note the ominous reference to “patient compliance” as a selling point.
Marry this technology to the ultraviolet fluorescing barcode tattoo (the aptly named Luciferase), and you’ve got a tracking system, banking modality, AND a sterilant. All in one.
Micron Biomedical
Who we are:
Micron develops pharmaceutical products, based on its proprietary microneedle patch technology, that are designed to provide enhanced vaccines and proprietary drugs efficacy, superior patient compliance, and simplified administration, distribution, and storage logistics.
Micron attends WHO meeting of experts on microneedle patches for measles vaccination
GENEVA, April 23, 2018 – The World Health Organization (WHO) invited Micron Biomedical, Inc. (Micron) to participate in a workshop on the development of microneedle patches for vaccination against measles. This meeting is taking place at the WHO headquarters in Geneva, Switzerland, April 23-24, 2018 and gathers experts from around the world on measles and microneedle patch technology. Attendees include members of the Bill & Melinda Gates Foundation (BMGF), WHO, Doctors Without Borders (MSF), Centers for Disease Control and Prevention (CDC), PATH, vaccine manufacturers, and microneedle patch companies. Micron will present its ongoing work on the development of a measles and rubella microneedle patch funded by BMGF and UNICEF.
Microneedle patch technology shows potential for long-acting contraception
ATLANTA, January 14, 2019 – The laboratory of Prof. Mark Prausnitz at Georgia Tech developed dissolving microneedle patches that administer a long-acting contraceptive for more than 30 days using microneedle technology licensed exclusively to Micron Biomedical. This work was published in the journal Nature Biomedical Engineering on January 14, 2019.
In the study conducted in animals, microneedle patches were designed to allow microneedles containing the contraceptive hormone levonorgestrel to break off their base within a few seconds following microneedle patch application to skin and, then, to slowly dissolve and deliver levonorgestrel for over a month with a single microneedle patch application. Because the microneedles break off quickly, it is not necessary for the microneedle patch backing to remain on the skin while the microneedles dissolve. Also, because the microneedle patches are applied by simply pressing to the skin by thumb, self-administration is envisioned.
The technology, licensed exclusively by Micron Biomedical, shows the potential to offer an attractive alternative to current long-acting contraceptive options, which can be costly and require an injection or the implantation of a device by a healthcare professional.
The global hormonal contraceptive market was valued $19.5B in 2017 and is expected to reach $30.0B by 2026.
The research article can be found at https://www.nature.com/articles/s41551-018-0337-4.